China Liquid Biopsy Market Size, Share, Trends & Forecast
The China Liquid Biopsy Market is expanding as healthcare providers increasingly look for non-invasive approaches to cancer detection and monitoring. The market was valued at USD 636.93 million in 2024 and is projected to reach USD 1.915 billion by 2035, registering a CAGR of 10.53% from 2025 to 2035.
Technological development is making liquid biopsy testing more accurate and useful in clinical settings. Next-generation sequencing, digital PCR, bioinformatics, microfluidics, and artificial intelligence are supporting the detection of circulating tumor DNA and other biomarkers. These improvements are also helping researchers explore more personalized approaches to cancer care.
Cancer diagnosis is the largest application area, while treatment monitoring is emerging as a faster-growing use as healthcare providers seek ways to assess treatment response without repeated invasive procedures. Blood is the dominant sample type, with urine gaining attention as another minimally invasive option.
Next-generation sequencing currently leads the technology segment, while digital PCR is growing quickly because of its sensitivity in identifying low-level genetic changes. Hospitals represent the largest end-user segment, while diagnostic laboratories are expanding their capabilities and adoption of liquid biopsy testing.
Future opportunities are likely to include portable liquid biopsy systems, improved biomarker identification, integrated diagnostic platforms, and personalized cancer testing. Continued advances in genomics and regulatory support for innovative diagnostics could further strengthen adoption across China's healthcare system.
Gain valuable insights through comprehensive industry analysis:
High-Flow Nasal Cannula Market Forecast
Animal Intestinal Health Market Outlook
Microarray Analysis Market Analysis